Pulmatrix licenses inhaled COPD drug to Vectura

Pulmatrix (NSDQ:PULM) said today that it licensed its inhaled COPD drug to Vectura.

The PUR0200 compound combines tiotropium bromide and Pulmatrix’s iSperse drug-delivery technology. Vectura plans to use its dry powder inhaler device to deliver PUR0200, the company said.

Get the full story at our sister site, Drug Delivery Business News.

The post Pulmatrix licenses inhaled COPD drug to Vectura appeared first on MassDevice.

from MassDevice http://ift.tt/2wGeIUu